

**Small Molecule Technologies**  
**Available for Licensing and co-development**  
<http://techtransfer.cancer.gov/availabletechnologies>

| Lead Inventor        | Title  | Therapeutic Area   | Reference #                              |
|----------------------|--|--|--|
| Barry O'Keefe        | Reverse Thiazine Kinase Inhibitors   | Rare/Neglected Diseases<br>Oncology<br>Infectious Disease  | <a href="#">TAB-5020</a><br>E-162-2024-0 |
| Yves Pommier         | Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers                                 | Oncology   | <a href="#">TAB-5033</a><br>E-075-2024-0 |
| Peng Jiang           | Acyloxyacyl Hydrolase (AOAH) and Methods of Use  | Oncology<br>Immunology                                     | <a href="#">TAB-5087</a><br>E-038-2024-0 |
| Barry O'Keefe        | Novel Kinase Inhibitory Aplithianines  | Rare/ Neglected Diseases<br>Oncology<br>Infectious Disease | <a href="#">TAB-5019</a><br>E-044-2022-0 |
| Kylie Walters        | Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins  | Oncology<br>Immunology                                     | <a href="#">TAB-5032</a><br>E-138-2023-0 |
| Shalini Oberdoerffer | Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies | Oncology<br>Neurology<br>Cardiology                        | <a href="#">TAB-4468</a><br>E-017-2023-0 |
| Barbara Felber       | Synergistic Interactions for Improved Cancer Treatment   | Oncology<br>Immunology                                     | <a href="#">TAB-5057</a><br>E-174-2022-0 |
| Barbara Felber       | Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response  | Oncology<br>Infectious Diseases                            | <a href="#">TAB-4123</a><br>E-158-2022-0 |
| Nigel Greig          | Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder                                     | Oncology<br>Neurology                                      | <a href="#">TAB-5045</a><br>E-151-2022-0 |
| John Brognard        | PIM-Targeted PROTACs   | Oncology   | <a href="#">TAB-4305</a><br>E-094-2022-0 |

**Small Molecule Technologies**  
**Available for Licensing and co-development**  
<http://techtransfer.cancer.gov/availabletechnologies>

|                     |   |   |  |
|---------------------|---|---|--|
| Yves Pommier        | Topoisomerase III (TOP3) Inhibitors and Antiviral Compounds based on Cyanine Dyes   | Infectious Diseases                     | <a href="#">TAB-3854</a><br>E-027-2022-0                                 |
| Genoveffa Franchini | High Efficacy Vaccine and Microbicide Combination for Use Against HIV   | Infectious Disease Immunology           | <a href="#">TAB-4406</a><br>E-048-2021-0                                 |
| Xue Zhao            | Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors                                   | TDP1 and TOP1 expressing cancers        | <a href="#">TAB-4201</a><br>E-256-2020-0                                 |
| Stavroula Mili      | Antisense Oligonucleotides against Cancer Cell Migration and Invasion   | Oncology                                | <a href="#">TAB-4256</a><br>E-041-2020-0                                 |
| Giovanna Tosato     | Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors | Oncology                                | <a href="#">TAB-4059</a><br>E-182-2019-0<br>E-182-2019-1<br>E-182-2019-2 |
| Udo Rudloff         | CD206 Small Molecule Modulators, Their Use and Methods for Preparation  | CD206- expressing cancers               | <a href="#">TAB-4342</a><br>E-105-2019-0                                 |
| Bruce Shapiro       | Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides  | Oncology                                | <a href="#">TAB-4260</a><br>E-065-2019-0                                 |
| Javed Khan          | Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers                                   | Neurology                               | <a href="#">TAB-4413</a><br>E-023-2019-0                                 |
| Berkley Gryder      | Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment                                      | Androgen receptor-positive solid tumors | <a href="#">Tab-4155</a><br>E-169-2018-0                                 |

**Small Molecule Technologies**  
**Available for Licensing and co-development**  
<http://techtransfer.cancer.gov/availabletechnologies>

|                     |   |   |  |
|---------------------|---|---|--|
| Bruce Shapiro       | siRNA Delivery Using Hexameric Tetrahedral RNA Nanostructures for Gene Silencing                                      | Oncology                                    | <a href="#">TAB-3943</a><br>E-075-2018-0<br>E-075-2018-1 |
| Stanislav Tomarev   | Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma                               | Ophthalmology                               | <a href="#">TAB-4170</a><br>E-044-2018-0                 |
| Christopher Ramsden | Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders | Pain, Autoimmune and Inflammatory disorders | <a href="#">TAB-4152</a><br>E-151-2017-0                 |
| Bruce Shapiro       | Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles  | Oncology<br>Infectious Disease              | <a href="#">TAB-4003</a><br>E-277-2016-0                 |
| John Schiller       | Efficient Cell-Free Production of Papillomavirus Gene Transfer Vectors  | Oncology,<br>Infectious Disease             | <a href="#">TAB-3932</a><br>E-298-2016-0                 |
| Bruce Shapiro       | RNA/DNA Nanoparticles as Cancer Therapeutics  | Oncology                                    | <a href="#">TAB-3873</a><br>E-078-2016-0                 |
| Nigel Greig         | Thalidomide Analogs that Inhibit Inflammation and Angiogenesis  | Oncology                                    | <a href="#">TAB-4062</a><br>E-208-2015-0                 |
| Kirk Gustafson      | Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors   | HIF-1 over-expressing cancers               | <a href="#">TAB-4447</a><br>E-115-2015-0                 |

**Small Molecule Technologies**  
**Available for Licensing and co-development**  
<http://techtransfer.cancer.gov/availabletechnologies>

|                        |  |                                       |  |
|------------------------|--|---------------------------------------|--|
| Molukutty Aryankalayil | Biomarker signature development: microRNAs for biodosimetry  | Oncology                              | <a href="#">TAB-4301</a><br>E-066-2015-0                                 |
| John Schneekloth       | Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex  | Oncology                              | <a href="#">TAB-4334</a><br>E-053-2015-0<br>E-053-2015-1                 |
| Christophe Marchand    | Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer  | Oncology                              | <a href="#">TAB-3930</a><br>E-275-2014-0                                 |
| Bruce Shapiro          | Nucleic Acid Nanoparticles for Triggering RNA Interference   | Oncology,<br>Infectious Diseases      | <a href="#">TAB-3965</a><br>E-156-2014-0<br>E-156-2014-1<br>E-156-2014-2 |
| James Doroshov         | Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions | Oncology<br>Immunology                | <a href="#">TAB-4148</a><br>E-116-2014-0                                 |
| John Beutler           | Renal Selective Unsaturated Englerin Analogues   | Small Molecule<br>Cancer Therapeutics | <a href="#">TAB-4191</a><br>E-072-2014-0                                 |
| Bruce Shapiro          | Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics   | Oncology,<br>Infectious Diseases      | <a href="#">TAB-4077</a><br>E-765-2013-0                                 |
| Bruce Shapiro          | Co-Transcriptional Assembly of Modified RNA Nanoparticles  | Oncology                              | <a href="#">TAB-3925</a><br>E-223-2012-0                                 |

**Small Molecule Technologies**  
**Available for Licensing and co-development**  
<http://techtransfer.cancer.gov/availabletechnologies>

|               |  |                               |  |
|---------------|--|-------------------------------|--|
| Bruce Shapiro | Nanoparticles for the targeted treatment of infected cells | Oncology, Infectious Diseases | <a href="#">TAB-4169</a><br>E-039-2012-0<br>E-039-2012-1<br>E-039-2012-2 |
|---------------|--|-------------------------------|--|

**Contact:**

Michael L. Salgaller, PhD | Supervisory Specialist | Email: [Michael.salgaller@nih.gov](mailto:Michael.salgaller@nih.gov) | Phone: (240) 276-5476  
Joseph M. Conrad III, PhD, JD | Senior Technology Transfer & Marketing Specialist |  
Email: [joseph.conrad@nih.gov](mailto:joseph.conrad@nih.gov) | Phone: (240) 276-5495